Immunization with autologous T cells enhances in vivo anti-tumor immune responses accompanied by up-regulation of GADD45β

Cell Research

Volumn 16, Issue 8, 2006, Pages 702-712

  Wang, Li ^a,b   Du, Fang ^a,b   Cao, Qi ^a,b   Sheng, Huiming ^a,b   Shen, Baihua ^a,b   Zhang, Yan ^a,b   Diao, Yingna ^a,b   Zhang, Jingwu ^a,b   Li, Ningli ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Immunology Institute   (China)

Author keywords

AICD; Anti tumor immunity; Autologous T cells; GADD45 ; Immunization

Indexed keywords

ANTINEOPLASTIC AGENT; DIFFERENTIATION ANTIGEN; FAS ANTIGEN; FAS LIGAND; GADD45B PROTEIN, MOUSE; INTERLEUKIN 12;

ANIMAL; ARTICLE; AUTOTRANSPLANTATION; C57BL MOUSE; CELL DEATH; CELL PROLIFERATION; CYTOLOGY; FEMALE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; NATURAL KILLER CELL; NEOPLASM; PHYSIOLOGY; RADIATION EXPOSURE; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL PROLIFERATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNIZATION; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; UP-REGULATION;

EID: 33747482209     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310083     Document Type: Article

References (45)

1. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein surviving in cancer patients. Cancer Res 2001; 61:869-872.
2. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T cell responses against surviving-derived MHC class I-restricted T cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61:5964-5968.
3. Cinatl Jr J, Scholz M, Doerr HW. Role of tumor cell immune escape mechanisms in cytomegalovirus-mediated oncomodulation. Med Res Rev 2005; 25:167-185.
4. Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother 2004; 27:329-338.
5. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type I (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190:617-627.
6. Fallarino F, Grohmann U, Bianchi R, Vacca C, Fioretti MC, Puccetti P. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol 2000; 165:5495-5501.
7. Yazawa T, Ito T, Kamma H, et al. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol 2002;161:291-300.
8. Acihini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177:989-995.
9. Surman D, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000; 164:562-565.
10. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-3633.
11. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci 2004; 101(Suppl 2):14567-14571.
12. Escobar A, Lopez M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142:555-568.
13. Hanada T, Yoshida H, Kato S, et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003; 19:437-450.
14. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001; 61:6445-6450.
15. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004; 22:1546-1553.
16. Graca L, Chen TC, Moine AL, et al. Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends Immunol 2005; 26:130-135.
17. Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology 2006;45:26-30.
18. Pardo J, Bosque A, Brehm R, et al. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol 2004; 167:457-468.
19. Chen SY, Yang A, Chen J, et al. Potent anti-tumor activities of a new class of tumor-specific killer cells. Nature 1997; 385:78-80.
20. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004;172:4599-4608.
21. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188:2199-2204.
22. Huang Y, Obholzer N, Fayad R, Qiao L. Turning on/off tumor-specific CTL response during progressive tumor growth. J Immunol 2005; 175:3110-3116.
23. Campi G, Crosti M, Consogno G, et al. CD4+ T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003; 63:8481-8488.
24. Hajnzic TF, Kastelan M, Lukac J, Hajnzic T. Immunocompetent cells and lymphocyte reactivity to mitogens in levamisole-treated brain tumor children. Pediatr Hematol Oncol 1999;16:335-340.
25. Tang J, Flomenberg P, Harshyne L, et al. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 2005;11:5292-5299.
26. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 1999; 82:442-451.
27. Liu SH, Zhang M, Zhang WG. Strategies of antigen-specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm 2005; 20:491-501.
28. Hong J, Zang Y, Tejada-Simon M, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination in patients with multiple sclerosis. J Immunol 2000; 165:6858-6864.
29. Shapira OM, Mor E, Reshef T, et al. Prolongation of survival of rat cardiac allografts by T cell vaccination. J Clin Invest 1993; 91:388-390.
30. Rakhmilevich AL, Timmins JG, Janssen K, et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother 1999; 22:135-144.
31. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93:1541-1552.
32. Kumar V, Sercarz E, Zhang JW, Cohen I. T cell vaccination: from basics to the clinic. Trends Immunol 2001; 22:539-544
33. Kozovska ME, Hong J, Zang YCQ, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999; 53:1692-1697.
34. Lockshin RA, Zakeri Z. Apoptosis, autophagy and more. Int Biochem Cell Biol 2004; 36:2405-2419.
35. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 1999; 77:312-317.
36. Greeneltch KM, Kelly-Welch AE, Shi Y, Keegan AD. Chronic morphine treatment promotes specific Th2 cytokine production by murine T cells in vitro via a Fas/Fas ligand-dependent mechanism. J Immunol 2005; 175:4999-5005.
37. Sun T, Zhou Y, Li H, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005; 202:967-974.
38. Mallone R, Kochik SA, Reijonen H, et al. Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood 2005; 106:2798-2805.
39. M Gupta, SK Gupta, AG Balliet, et al. Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis. Oncogene 2005; 24:7170-7179.
40. Papa S, Zazzeroni F, Pham CG, et al. Linking JNK signaling to NF-κB: a key to survival. J Cell Sci 2004; 117:5197-5208.
41. Lu BF, Ferrandino AF, Flavell RA, et al. Gadd45b is important for perpetuating cognate and inflammatory signals in T cells. Nat Immunol 2004; 5:38-44.
42. Chi H, Lu BF, Takekawa M, Davis RJ, Flavell RA. GADD45b/GADD45c and MEKK4 comprise a genetic pathway mediating STAT4-independent IFNγ production in T cells. EMBO J 2004; 23:1576-1586.
43. Yang J, Zhu H, Murphy TL, et al. IL-18-stimulated GADD45 required in cytokine-induced, but not TCR-induced, IFN-γ production. Nat Immunol 2001; 2:157-164.
44. Mittal A, Papa S, Franzoso G, Sen RJ. NF-κB-dependent regulation of the timing of activation-induced cell death of T lymphocytes. J Immunol 2006; 176:2183-2189.
45. Azzzeroni F, Papa S, Algeciras-Schimnich A, et al. GADD45β-mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood 2003; 102:3270-3279.